Archives For truth on the market

In recent years, the European Union’s (EU) administrative body, the European Commission (EC), increasingly has applied European competition law in a manner that undermines free market dynamics.  In particular, its approach to “dominant” firm conduct disincentivizes highly successful companies from introducing product and service innovations that enhance consumer welfare and benefit the economy – merely because they threaten to harm less efficient competitors.

For example, the EC fined Microsoft 561 million euros in 2013 for its failure to adhere to an order that it offer a version of its Window software suite that did not include its popular Windows Media Player (WMP) – despite the lack of consumer demand for a “dumbed down” Windows without WMP.  This EC intrusion into software design has been described as a regulatory “quagmire.”

In June 2017 the EC fined Google 2.42 billion euros for allegedly favoring its own comparison shopping service over others favored in displaying Google search results – ignoring economic research that shows Google’s search policies benefit consumers.  Google also faces potentially higher EC antitrust fines due to alleged abuses involving android software (bundling of popular Google search and Chrome apps), a product that has helped spur dynamic smartphone innovations and foster new markets.

Furthermore, other highly innovative single firms, such as Apple and Amazon (favorable treatment deemed “state aids”), Qualcomm (alleged anticompetitive discounts), and Facebook (in connection with its WhatsApp acquisition), face substantial EC competition law penalties.

Underlying the EC’s current enforcement philosophy is an implicit presumption that innovations by dominant firms violate competition law if they in any way appear to disadvantage competitors.  That presumption forgoes considering the actual effects on the competitive process of dominant firm activities.  This is a recipe for reduced innovation, as successful firms “pull their competitive punches” to avoid onerous penalties.

The European Court of Justice (ECJ) implicitly recognized this problem in its September 6, 2017 decision setting aside the European General Court’s affirmance of the EC’s 2009 1.06 billion euro fine against Intel.  Intel involved allegedly anticompetitive “loyalty rebates” by Intel, which allowed buyers to achieve cost savings in Intel chip purchases.  In remanding the Intel case to the General Court for further legal and factual analysis, the ECJ’s opinion stressed that the EC needed to do more than find a dominant position and categorize the rebates in order to hold Intel liable.  The EC also needed to assess the “capacity of [Intel’s] . . . practice to foreclose competitors which are at least as efficient” and whether any exclusionary effect was outweighed by efficiencies that also benefit consumers.  In short, evidence-based antitrust analysis was required.  Mere reliance on presumptions was not enough.  Why?  Because competition on the merits is centered on the recognition that the departure of less efficient competitors is part and parcel of consumer welfare-based competition on the merits.  As the ECJ cogently put it:

[I]t must be borne in mind that it is in no way the purpose of Article 102 TFEU [which prohibits abuse of a dominant position] to prevent an undertaking from acquiring, on its own merits, the dominant position on a market.  Nor does that provision seek to ensure that competitors less efficient than the undertaking with the dominant position should remain on the market . . . .  [N]ot every exclusionary effect is necessarily detrimental to competition. Competition on the merits may, by definition, lead to the departure from the market or the marginalisation of competitors that are less efficient and so less attractive to consumers from the point of view of, among other things, price, choice, quality or innovation[.]

Although the ECJ’s recent decision is commendable, it does not negate the fact that Intel had to wait eight years to have its straightforward arguments receive attention – and the saga is far from over, since the General Court has to address this matter once again.  These sorts of long-term delays, during which firms face great uncertainty (and the threat of further EC investigations and fines), are antithetical to innovative activity by enterprises deemed dominant.  In short, unless and until the EC changes its competition policy perspective on dominant firm conduct (and there are no indications that such a change is imminent), innovation and economic dynamism will suffer.

Even if the EC dithers, the United Kingdom’s (UK) imminent withdrawal from the EU (Brexit) provides it with a unique opportunity to blaze a new competition policy trail – and perhaps in so doing influence other jurisdictions.

In particular, Brexit will enable the UK’s antitrust enforcer, the Competition and Markets Authority (CMA), to adopt an outlook on competition policy in general – and on single firm conduct in particular – that is more sensitive to innovation and economic dynamism.  What might such a CMA enforcement policy look like?  It should reject the EC’s current approach.  It should focus instead on the actual effects of competitive activity.  In particular, it should incorporate the insights of decision theory (see here, for example) and place great weight on efficiencies (see here, for example).

Let us hope that the CMA acts boldly – carpe diem.  Such action, combined with other regulatory reforms, could contribute substantially to the economic success of Brexit (see here).

U.S. international trade law has various statutory mechanisms to deal with unfair competition.  Regrettably, American trade law (and, for that matter, the trade laws of other nations) has a history of being deployed in a mercantilist fashion to further the interests of American producer interests, rather than consumer interests and aggregate economic welfare.  That need not, however, necessarily be the case.

For example, instead of penalizing more efficient imports, American antidumping law could be reoriented to deal only with true predatory pricing, thereby promoting free market interests (see my proposal here).  And section 337 of the Tariff Act, directed at “unfair methods of competition” in import trade, could be employed in a non-protectionist manner that enhances market efficiency by focusing exclusively on foreign harm to U.S. intellectual property (IP) rights (see my proposal here).

Countervailing duty (CVD) law, which applies tariffs to counteract foreign government subsidies, could be a force for eliminating government-imposed competitive distortions – and for discouraging governments from conferring subsidies to favored industries or firms in the first place.  In practice, however, significant distortive government subsidies to key industries have persisted in the face of CVD statutes.  The application of countervailing duties and the raising of CVD disputes to the World Trade Organization have proven to be inadequate in curbing governments’ persistent efforts to subsidize corporate favorites, while preventing trading partners from bestowing similar largesse on their national champions.

Among the beneficiaries of major subsidies that lead to international trade disputes, the commercial aircraft sector, dominated by the longstanding Boeing and Airbus duopoly, stands out.  A recent article by trade law expert Shanker Singham, Director of Economic Policy and Prosperity Studies at the United Kingdom’s Legatum Institute, highlights the economic deficiencies revealed by the most recent battle in the ongoing commercial aircraft “subsidies war” saga.

Specifically, Singham suggests reforming countervailable subsidies with a “trade remedy law based on evaluating distortions and their effects”.  Singham’s article, “America’s Protectionism Is Damaging British Interests,” is worth a careful read:

Theresa May was recently in Canada meeting the Canadian PM, Justin Trudeau, to discuss how theyshould react to a trade case that Boeing has brought against Bombardier, Canada’s aerospace manufacturer. The case could affect 4,000 jobs in Bombardier’s Belfast facility. From Belfast, this might look like the vagaries of international trade, but the real story runs deeper.

Competition among producers of aircraft has been fierce, and has also been often accompanied by complaints about state subsidies and other trade distortions. Civil aviation is a sector that has been plagued by government interventions all over the world, and to say that the playing field is not level is an understatement.

While Airbus subsidies are its usual target, Boeing has recently turned its fire onto Bombardier, claiming that the Canadian jet manufacturer has dumped product into the US market. Boeing is citing US trade remedy laws, the price-based focus of which makes them prone to this sort of protectionist abuse.

The UK has been dragged in to the row because jobs in Belfast depend on the production of key inputs into the Bombardier plane. So just as the people of Northern Ireland are struggling with Brexit, they face a fresh concern not of their own making.

Our recently released [Legatum Institute] paper on Northern Ireland discusses the need to find ways of promoting economic activity in Northern Ireland using Special Economic Zones, among other ways of minimising the costs of Brexit. And one idea is that the people of Northern Ireland should benefit from UK-US trade agreements as we set out in our Transatlantic partnership paper.

But allowing the abuse of notoriously protectionist trade remedy laws in the US to have a completely unjustifiable and knock-on effect in Northern Ireland would not indicate the good UK-US trade relations that the Trump administration has promised.

The Prime Minister has recognised the danger, and raised the issue in a call with President Trump, as well with Trudeau this week. Voices within her own party, and the media, are calling for her to take a tougher line against Boeing to protect those jobs in Northern Ireland, and others in the supply chain across the UK.

But what could the Prime Minister do?

The case highlights the trade barrier that the trade remedies themselves pose and shows why reform is necessary. Given that new UK trade remedy laws must be developed as a result of Brexit, and the US-UK agreement, here is an excellent opportunity to deal with those government interventions that distort trade by focusing on the source of the problem – and not on pricing (as current trade remedy laws do).

For trade to be fair, we need to make sure that distortions are reduced in all our markets, and that any trade remedies we use are designed to deal with these distortions.

In the case of the production of aircraft (large-body), Boeing and Airbus have been at each other’s throats, each maintaining that the other is subsidised or supported by governments. Recently, Airbus lost a case in the WTO where it was arguing that Boeing’s Washington state incentives violated WTO rules on subsidies. That case was in response to a series of cases which Boeing had brought against Airbus. It highlights the problem of the WTO’s approach to subsidies and government support in general.

Whether the government privilege or grant is given federally or through a state, what matters is whether the cost of production has been reduced by ordinary business processes and efficiency, or whether in fact it has been reduced through government action. Viewed through this lens, very few aircraft manufacturers have clean hands.

However, while these distortions abound, bringing trade remedy cases that ignore the complainants’ own network of distortions and subsidies is patently unfair. The Boeing case has effects in Canada, but because we are in a world of competing global supply chains, these effects reverberate around the world.

All the suppliers to Bombardier, including those based in Northern Ireland, are adversely affected when US firms use the US trade remedy laws to damage trade between nations. These laws were written at a time when we did not live in a world of global supply chains, but rather a world where firms produced products in country A and sold them in country B.  They do not fit within our new world of complex supply chains.

It is high time that countries around the world ensured that their domestic policies and their external trade policies lined up. Countries such as the US cannot argue that they intend to do trade deals with the UK, if their domestic measures damage the interests of that trading partner.

In fact, the UK and the US have an opportunity here to use trade remedy measures to attack products from companies whose costs are artificially lowered as a result of government distortion, as opposed to being more competitive. Boeing’s case, however, does not differentiate between the two – which is why it is flawed.

In the UK, there is talk of using a public interest test in the application of trade remedy laws. Such a test could look at the impact of the use of these remedies on international trade and on consumers.

Theresa May has argued for industrial strategy in ways that give those of us who believe in the power of free trade and free markets pause. But in this case, the most basic industrial strategy has to be to defend UK production, such as the plant in Belfast, from the effects of distortions in other markets, and the abuse of trade remedy laws.

A trade remedy law based on evaluating distortions and their effects would prevent this. It is something the UK and US may be able to agree, and it is certainly something that the UK could lead on by example.

If the UK government seeks to protect its workers in this case, this should not be seen as a protectionist gesture.  It would be a necessary response to US protectionism. As long as countries maintain laws on their books that allow consumers to be damaged, and supply chains to be adversely affected, countries may seek to use other means to retaliate against the offender.

World trade is under sufficient threat, at the moment not to freight it down with additional and quite unnecessary challenges, such as over-vigorous use of anti-dumping laws. The UK has a great opportunity to lead this debate as it formulates its own independent trade policy.

As Singham’s article suggests, U.S.-UK free trade negotiations made possible by Brexit create the possibility for the reformulation of American CVD law to focus on actual distortions of competition.  CVD assessments calibrated precisely to the amount of the foreign government’s distortionary subsidy, applied first in the context of US-UK trade, could serve as a model for the more general reform of American (and UK) CVD law.  This in turn might serve as a template for more general CVD reform, through bilateral or plurilateral deals – and perhaps eventually a global deal under the auspices of the World Trade Organization.  Think big.

 

Last Friday, drug maker Allergan and the Saint Regis Mohawk Tribe announced that they had reached an agreement under which Allergan assigned the patents on its top-selling drug Restasis to the tribe and, in return, Allergan was given the exclusive license on the Restasis patents so that it can continue producing and distributing the drug.  Allergan agreed to pay $13.75 million to the tribe for the deal, and up to $15 million annually in royalties as long as the patents remain valid.

Why would a large drug maker assign the patents on a leading drug to a sovereign Indian nation?  This unorthodox agreement may actually be a brilliant strategy that enables patent owners to avoid the unbalanced inter partes review (IPR) process.  The validity of the Restasis patents is currently being challenged both in IPR proceedings before the Patent Trial and Appeal Board (PTAB) and in federal district court in Texas.  However, the Allergan-Mohawk deal may lead to the dismissal of the IPR proceedings as, under the terms of the deal, the Mohawks will file a motion to dismiss the IPR proceedings based on the tribe’s sovereign immunity.  Earlier this year, in Covidien v. University of Florida Research Foundation, the PTAB determined that sovereign immunity shields state universities holding patents from IPR proceedings, and the same reasoning should certainly apply to sovereign Indian nations.

I’ve published a previous article explaining why pharmaceutical companies have legitimate reasons to avoid IPR proceedings–critical differences between district court litigation and IPR proceedings jeopardize the delicate balance Hatch-Waxman sought to achieve between patent owners and patent challengers. In addition to forcing patent owners into duplicative litigation in district courts and the PTAB, depriving them of the ability to achieve finality in one proceeding, the PTAB also applies a lower standard of proof for invalidity than do district courts in Hatch-Waxman litigation.  It is also easier to meet the standard of proof in a PTAB trial because of a more lenient claim construction standard.  Moreover, on appeal, PTAB decisions in IPR proceedings are given more deference than lower district court decisions.  Finally, while patent challengers in district court must establish sufficient Article III standing, IPR proceedings do not have a standing requirement.  This has led to the exploitation of the IPR process by entities that would never be granted standing in traditional patent litigation—hedge funds betting against a company by filing an IPR challenge in hopes of crashing the stock and profiting from the bet.

The differences between district court litigation and IPR proceedings have created a significant deviation in patent invalidation rates under the two pathways; compared to district court challenges, patents are twice as likely to be found invalid in IPR challenges.  Although the U.S. Supreme Court in Cuozzo Speed Technologies v. Lee concluded that the anti-patentee claim construction standard in IPR “increases the possibility that the examiner will find the claim too broad (and deny it)”, the Court concluded that only Congress could mandate a different standard.  So far, Congress has done nothing to reduce the disparities between IPR proceedings and Hatch-Waxman litigation. But, while we wait, the high patent invalidation rate in IPR proceedings creates significant uncertainty for patent owners’ intellectual property rights.   Uncertain patent rights, in turn, lead to less innovation in the pharmaceutical industry.  Put simply, drug companies will not spend the billions of dollars it typically costs to bring a new drug to market when they can’t be certain if the patents for that drug can withstand IPR proceedings that are clearly stacked against them (for an excellent discussion of how the PTAB threatens innovation, see Alden Abbot’s recent TOTM post).  Thus, deals between brand companies and sovereigns, such as Indian nations, that insulate patents from IPR proceedings should improve the certainty around intellectual property rights and protect drug innovation.

Yet, the response to the Allergan-Mohawk deal among some scholars and generic drug companies has been one of panic and speculative doom.  Critics have questioned the deal largely on the grounds that, in addition to insulating Restasis from IPR proceedings, tribal sovereignty might also shield the patents in standard Hatch-Waxman district court litigation.  If this were true and brand companies began to routinely house their patents with sovereign Indian nations, then the venues in which generic companies could challenge patents would be restricted and generic companies would have less incentive to produce and market cheaper drugs.

However, it is far from clear that these deals could shield patents in standard Hatch-Waxman district court litigation.  Hatch-Waxman litigation typically follows a familiar pattern: a generic company files a Paragraph IV ANDA alleging patent owner’s patents are invalid or will not be infringed, the patent owner then sues the generic for infringement, and then the generic company files a counterclaim for invalidity.  Critics of the Allergan-Mohawk deal allege that tribal sovereignty could insulate patent owners from the counterclaim.  However, courts have held that state universities waive sovereign immunity for counterclaims when they file the initial patent infringement suit.  Although, in non-infringement contexts, tribes have been found to not waive sovereign immunity for counterclaims merely by filing an action as a plaintiff, this has never been tested in patent litigation.  Moreover, even if sovereign immunity could be used to prevent the counterclaim, invalidity can still be raised as an affirmative defense in the patent owner’s infringement suit (although it has been asserted that requiring generics to assert invalidity as an affirmative defense instead of a counterclaim may still tilt the playing field toward patent owners).  Finally, many patent owners that are sovereigns may choose to voluntarily waive sovereign immunity to head off any criticism or congressional meddling. Given the uncertainty of the effects of tribal sovereignty in Hatch-Waxman litigation, Allergan has concluded that their deal with the Mohawks won’t affect the pending district court litigation involving the validity of the Restasis patents.  However, if tribes in future cases were to cloud the viability of Hatch-Waxman by asserting sovereign immunity in district court litigation, Congress could always respond by altering the Hatch-Waxman rules to preclude this.

For now, we should all take a deep breath and put the fearmongering on hold.  Whether deals like the Allergan-Mohawk arrangement could affect Hatch-Waxman litigation is simply a matter of speculation, and there are many reasons to believe that they won’t. In the meantime, the deal between Allergan and the Saint Regis Mohawk Tribe is an ingenious strategy to avoid the unbalanced IPR process.   This move is the natural extension of the PTAB’s ruling on state university sovereign immunity, and state universities are likely incorporating the advantage into their own licensing and litigation strategies.  The Supreme Court will soon hear a case questioning the constitutionality of the IPR process.  Until the courts or Congress act to reduce the disparities between IPR proceedings and Hatch-Waxman litigation, we can hardly blame patent owners from taking clever legal steps to avoid the unbalanced IPR process.

On August 14, the Federalist Society’s Regulatory Transparency Project released a report detailing the harm imposed on innovation and property rights by the Patent Trial and Appeals Board, a Patent and Trademark Office patent review agency created by the infelicitously-named “America Invents Act” of 2011.  As the report’s abstract explains:

Patents are property rights secured to inventors of new products or services, such as the software and other high-tech innovations in our laptops and smart phones, the life-saving medicines prescribed by our doctors, and the new mechanical designs that make batteries more efficient and airplane engines more powerful. Many Americans first learn in school about the great inventors who revolutionized our lives with their patented innovations, such as Thomas Edison (the light bulb and record player), Alexander Graham Bell (the telephone), Nikola Tesla (electrical systems), the Wright brothers (airplanes), Charles Goodyear (cured rubber), Enrico Fermi (nuclear power), and Samuel Morse (the telegraph). These inventors and tens of thousands of others had the fruits of their inventive labors secured to them by patents, and these vital property rights have driven America’s innovation economy for over 225 years. For this reason, the United States has long been viewed as having the “gold standard” patent system throughout the world.

In 2011, Congress passed a new law, called the America Invents Act (AIA), that made significant changes to the U.S. patent system. Among its many changes, the AIA created a new administrative tribunal for invalidating “bad patents” (patents mistakenly issued because the claimed inventions were not actually new or because they suffer from other defects that create problems for companies in the innovation economy). This administrative tribunal is called the Patent Trial & Appeal Board (PTAB). The PTAB is composed of “administrative patent judges” appointed by the Director of the United States Patent & Trademark Office (USPTO). The PTAB administrative judges are supposed to be experts in both technology and patent law. They hold administrative hearings in response to petitions that challenge patents as defective. If they agree with the challenger, they cancel the patent by declaring it “invalid.” Anyone in the world willing to pay a filing fee can file a petition to invalidate any patent.

As many people are aware, administrative agencies can become a source of costs and harms that far outweigh the harms they were created to address. This is exactly what has happened with the PTAB. This administrative tribunal has become a prime example of regulatory overreach

Congress created the PTAB in 2011 in response to concerns about the quality of patents being granted to inventors by the USPTO. Legitimate patents promote both inventive activity and the commercial development of inventions into real-world innovation used by regular people the world over. But “bad patents” clog the intricate gears of the innovation economy, deterring real innovators and creating unnecessary costs for companies by enabling needless and wasteful litigation. The creation of the PTAB was well intended: it was supposed to remove bad patents from the innovation economy. But the PTAB has ended up imposing tremendous and unnecessary costs and creating destructive uncertainty for the innovation economy.

In its procedures and its decisions, the PTAB has become an example of an administrative tribunal run amok. It does not provide basic legal procedures to patent owners that all other property owners receive in court. When called upon to redress these concerns, the courts have instead granted the PTAB the same broad deference they have given to other administrative agencies. Thus, these problems have gone uncorrected and unchecked. Without providing basic procedural protections to all patent owners, the PTAB has gone too far with its charge of eliminating bad patents. It is now invalidating patents in a willy-nilly fashion. One example among many is that, in early 2017, the PTAB invalidated a patent on a new MRI machine because it believed this new medical device was an “abstract idea” (and thus unpatentable).

The problems in the PTAB’s operations have become so serious that a former federal appellate chief judge has referred to PTAB administrative judges as “patent death squads.” This metaphor has proven apt, even if rhetorically exaggerated. Created to remove only bad patents clogging the innovation economy, the PTAB has itself begun to clog innovation — killing large numbers of patents and casting a pall of uncertainty over every patent that might become valuable and thus a target of a PTAB petition to invalidate it.

The U.S. innovation economy has thrived because inventors know they can devote years of productive labor and resources into developing their inventions for the marketplace, secure in the knowledge that their patents provide a solid foundation for commercialization. Pharmaceutical companies depend on their patents to recoup billions of dollars in research and development of new drugs. Venture capitalists invest in startups on the basis of these vital property rights in new products and services, as viewers of Shark Tank see every week.

The PTAB now looms over all of these inventive and commercial activities, threatening to cancel a valuable patent at any moment and without rhyme or reason. In addition to the lost investments in the invalidated patents themselves, this creates uncertainty for inventors and investors, undermining the foundations of the U.S. innovation economy.

This paper explains how the PTAB has become a prime example of regulatory overreach. The PTAB administrative tribunal is creating unnecessary costs for inventors and companies, and thus it is harming the innovation economy far beyond the harm of the bad patents it was created to remedy. First, we describe the U.S. patent system and how it secures property rights in technological innovation. Second, we describe Congress’s creation of the PTAB in 2011 and the six different administrative proceedings the PTAB uses for reviewing and canceling patents. Third, we detail the various ways that the PTAB is now causing real harm, through both its procedures and its substantive decisions, and thus threatening innovation.

The PTAB has created fundamental uncertainty about the status of all patent rights in inventions. The result is that the PTAB undermines the market value of patents and frustrates the role that these property rights serve in the investment in and commercial development of the new technological products and services that make many aspects of our modern lives seem like miracles.

In June 2017, the U.S. Supreme Court agreed to review the Oil States Energy case, raising the question of whether PTAB patent review “violates the Constitution by extinguishing private property rights through a non-Article III forum without a jury.”  A Supreme Court finding of unconstitutionality would be ideal.  But in the event the Court leaves PTAB patent review intact, legislation to curb the worst excesses of PTAB – such as the bipartisan “STRONGER Patent Act of 2017” – merits serious consideration.  Stay tuned – I will have more to say in detail about potential patent law reforms, including the reining in of PTAB, in the near future.

On July 24, as part of their newly-announced “Better Deal” campaign, congressional Democrats released an antitrust proposal (“Better Deal Antitrust Proposal” or BDAP) entitled “Cracking Down on Corporate Monopolies and the Abuse of Economic and Political Power.”  Unfortunately, this antitrust tract is really an “Old Deal” screed that rehashes long-discredited ideas about “bigness is badness” and “corporate abuses,” untethered from serious economic analysis.  (In spirit it echoes the proposal for a renewed emphasis on “fairness” in antitrust made by then Acting Assistant Attorney General Renata Hesse in 2016 – a recommendation that ran counter to sound economics, as I explained in a September 2016 Truth on the Market commentary.)  Implementation of the BDAP’s recommendations would be a “worse deal” for American consumers and for American economic vitality and growth.

The BDAP’s Portrayal of the State of Antitrust Enforcement is Factually Inaccurate, and it Ignores the Real Problems of Crony Capitalism and Regulatory Overreach

The Better Deal Antitrust Proposal begins with the assertion that antitrust has failed in recent decades:

Over the past thirty years, growing corporate influence and consolidation has led to reductions in competition, choice for consumers, and bargaining power for workers.  The extensive concentration of power in the hands of a few corporations hurts wages, undermines job growth, and threatens to squeeze out small businesses, suppliers, and new, innovative competitors.  It means higher prices and less choice for the things the American people buy every day. . .  [This is because] [o]ver the last thirty years, courts and permissive regulators have allowed large companies to get larger, resulting in higher prices and limited consumer choice in daily expenses such as travel, cable, and food and beverages.  And because concentrated market power leads to concentrated political power, these companies deploy armies of lobbyists to increase their stranglehold on Washington.  A Better Deal on competition means that we will revisit our antitrust laws to ensure that the economic freedom of all Americans—consumers, workers, and small businesses—come before big corporations that are getting even bigger.

This statement’s assertions are curious (not to mention problematic) in multiple respects.

First, since Democratic administrations have held the White House for sixteen of the past thirty years, the BDAP appears to acknowledge that Democratic presidents have overseen a failed antitrust policy.

Second, the broad claim that consumers have faced higher prices and limited consumer choice with regard to their daily expenses is baseless.  Indeed, internet commerce and new business models have sharply reduced travel and entertainment costs for the bulk of American consumers, and new “high technology” products such as smartphones and electronic games have been characterized by dramatic improvements in innovation, enhanced variety, and relatively lower costs.  Cable suppliers face vibrant competition from competitive satellite providers, fiberoptic cable suppliers (the major telcos such as Verizon), and new online methods for distributing content.  Consumer price inflation has been extremely low in recent decades, compared to the high inflationary, less innovative environment of the 1960s and 1970s – decades when federal antitrust law was applied much more vigorously.  Thus, the claim that weaker antitrust has denied consumers “economic freedom” is at war with the truth.

Third, the claim that recent decades have seen the creation of “concentrated market power,” safe from antitrust challenge, ignores the fact that, over the last three decades, apolitical government antitrust officials under both Democratic and Republican administrations have applied well-accepted economic tools (wielded by the scores of Ph.D. economists in the Justice Department and Federal Trade Commission) in enforcing the antitrust laws.  Antitrust analysis has used economics to focus on inefficient business conduct that would maintain or increase market power, and large numbers of cartels have been prosecuted and questionable mergers (including a variety of major health care and communications industry mergers) have been successfully challenged.  The alleged growth of “concentrated market power,” untouched by incompetent antitrust enforcers, is a myth.  Furthermore, claims that mere corporate size and “aggregate concentration” are grounds for antitrust concern (“big is bad”) were decisively rejected by empirical economic research published in the 1970s, and are no more convincing today.  (As I pointed out in a January 2017 blog posting at this site, recent research by highly respected economists debunks a few claims that federal antitrust enforcers have been “excessively tolerant” of late in analyzing proposed mergers.)

More interesting is the BDAP’s claim that “armies of [corporate] lobbyists” manage to “increase their stranglehold on Washington.”  This is not an antitrust concern, however, but, rather, a complaint against crony capitalism and overregulation, which became an ever more serious problem under the Obama Administration.  As I explained in my October 2016 critique of the American Antitrust Institute’s September 2008 National Competition Policy Report (a Report which is very similar in tone to the BDAP), the rapid growth of excessive regulation during the Obama years has diminished competition by creating new regulatory schemes that benefit entrenched and powerful firms (such as Dodd-Frank Act banking rules that impose excessive burdens on smaller banks).  My critique emphasized that, “as Dodd-Frank and other regulatory programs illustrate, large government rulemaking schemes often are designed to favor large and wealthy well-connected rent-seekers at the expense of smaller and more dynamic competitors.”  And, more generally, excessive regulatory burdens undermine the competitive process, by distorting business decisions in a manner that detracts from competition on the merits.

It follows that, if the BDAP really wanted to challenge “unfair” corporate advantages, it would seek to roll back excessive regulation (see my November 2012 article on Trump Administration competition policy).  Indeed, the Trump Administration’s regulatory reform program (which features agency-specific regulatory reform task forces) seeks to do just that.  Perhaps then the BDAP could be rewritten to focus on endorsing President Trump’s regulatory reform initiative, rather than emphasizing a meritless “big is bad” populist antitrust policy that was consigned to the enforcement dustbin decades ago.

The BDAP’s Specific Proposals Would Harm the Economy and Reduce Consumer Welfare

Unfortunately, the BDAP does more than wax nostalgic about old-time “big is bad” antitrust policy.  It affirmatively recommends policy changes that would harm the economy.

First, the BDAP would require “a broader, longer-term view and strong presumptions that market concentration can result in anticompetitive conduct.”  Specifically, it would create “new standards to limit large mergers that unfairly consolidate corporate power,” including “mergers [that] reduce wages, cut jobs, lower product quality, limit access to services, stifle innovation, or hinder the ability of small businesses and entrepreneurs to compete.”  New standards would also “explicitly consider the ways in which control of consumer data can be used to stifle competition or jeopardize consumer privacy.”

Unlike current merger policy, which evaluates likely competitive effects, centered on price and quality, estimated in economically relevant markets, these new standards are open-ended.  They could justify challenges based on such a wide variety of factors that they would incentivize direct competitors not to merge, even in cases where the proposed merged entity would prove more efficient and able to enhance quality or innovation.  Certain less efficient competitors – say small businesses – could argue that they would be driven out of business, or that some jobs in the industry would disappear, in order to prompt government challenges.  But such challenges would tend to undermine innovation and business improvements, and the inevitable redistribution of assets to higher-valued uses that is a key benefit of corporate reorganizations and acquisitions.  (Mergers might focus instead, for example, on inefficient conglomerate acquisitions among companies in unrelated industries, which were incentivized by the overly strict 1960s rules that prohibited mergers among direct competitors.)  Such a change would represent a retreat from economic common sense, and be at odds with consensus economically-sound merger enforcement guidance that U.S. enforcers have long recommended other countries adopt.  Furthermore, questions of consumer data and privacy are more appropriately dealt with as consumer protection questions, which the Federal Trade Commission has handled successfully for years.

Second, the BDAP would require “frequent, independent [after-the-fact] reviews of mergers” and require regulators “to take corrective measures if they find abusive monopolistic conditions where previously approved [consent decree] measures fail to make good on their intended outcomes.”

While high profile mergers subject to significant divestiture or other remedial requirements have in appropriate circumstances included monitoring requirements, the tone of this recommendation is to require that far more mergers be subjected to detailed and ongoing post-acquisition reviews.  The cost of such monitoring is substantial, however, and routine reliance on it (backed by the threat of additional enforcement actions based merely on changing economic conditions) could create excessive caution in the post-merger management of newly-consolidated enterprises.  Indeed, potential merged parties might decide in close cases that this sort of oversight is not worth accepting, and therefore call off potentially efficient transactions that would have enhanced economic welfare.  (The reality of enforcement error cost, and the possibility of misdiagnosis of post-merger competitive conditions, is not acknowledged by the BDAP.)

Third, a newly created “competition advocate” independent of the existing federal antitrust enforcers would be empowered to publicly recommend investigations, with the enforcers required to justify publicly why they chose not to pursue a particular recommended investigation.  The advocate would ensure that antitrust enforcers are held “accountable,” assure that complaints about “market exploitation and anticompetitive conduct” are heard, and publish data on “concentration and abuses of economic power” with demographic breakdowns.

This third proposal is particularly egregious.  It is at odds with the long tradition of prosecutorial discretion that has been enjoyed by the federal antitrust enforcers (and law enforcers in general).  It would also empower a special interest intervenor to promote the complaints of interest groups that object to efficiency-seeking business conduct, thereby undermining the careful economic and legal analysis that is consistently employed by the expert antitrust agencies.  The references to “concentration” and “economic power” clarify that the “advocate” would have an untrammeled ability to highlight non-economic objections to transactions raised by inefficient competitors, jealous rivals, or self-styled populists who object to excessive “bigness.”  This would strike at the heart of our competitive process, which presumes that private parties will be allowed to fulfill their own goals, free from government micromanagement, absent indications of a clear and well-defined violation of law.  In sum, the “competition advocate” is better viewed as a “special interest” advocate empowered to ignore normal legal constraints and unjustifiably interfere in business transactions.  If empowered to operate freely, such an advocate (better viewed as an albatross) would undoubtedly chill a wide variety of business arrangements, to the detriment of consumers and economic innovation.

Finally, the BDAP refers to a variety of ills that are said to affect specific named industries, in particular airlines, cable/telecom, beer, food prices, and eyeglasses.  Airlines are subject to a variety of capacity limitations (limitations on landing slots and the size/number of airports) and regulatory constraints (prohibitions on foreign entry or investment) that may affect competitive conditions, but airlines mergers are closely reviewed by the Justice Department.  Cable and telecom companies face a variety of federal, state, and local regulations, and their mergers also are closely scrutinized.  The BDAP’s reference to the proposed AT&T/Time Warner merger ignores the potential efficiencies of this “vertical” arrangement involving complementary assets (see my coauthored commentary here), and resorts to unsupported claims about wrongful “discrimination” by “behemoths” – issues that in any event are examined in antitrust merger reviews.  Unsupported references to harm to competition and consumer choice are thrown out in the references to beer and agrochemical mergers, which also receive close economically-focused merger scrutiny under existing law.  Concerns raised about the price of eyeglasses ignore the role of potentially anticompetitive regulation – that is, bad government – in harming consumer welfare in this sector.  In short, the alleged competitive “problems” the BDAP raises with respect to particular industries are no more compelling than the rest of its analysis.  The Justice Department and Federal Trade Commission are hard at work applying sound economics to these sectors.  They should be left to do their jobs, and the BDAP’s industry-specific commentary (sadly, like the rest of its commentary) should be accorded no weight.

Conclusion

Congressional Democrats would be well-advised to ditch their efforts to resurrect the counterproductive antitrust policy from days of yore, and instead focus on real economic problems, such as excessive and inappropriate government regulation, as well as weak protection for U.S. intellectual property rights, here and abroad (see here, for example).  Such a change in emphasis would redound to the benefit of American consumers and producers.

 

 

On July 10, the Consumer Financial Protection Bureau (CFPB) announced a new rule to ban financial service providers, such as banks or credit card companies, from using mandatory arbitration clauses to deny consumers the opportunity to participate in a class action (“Arbitration Rule”).  The Arbitration Rule’s summary explains:

First, the final rule prohibits covered providers of certain consumer financial products and services from using an agreement with a consumer that provides for arbitration of any future dispute between the parties to bar the consumer from filing or participating in a class action concerning the covered consumer financial product or service. Second, the final rule requires covered providers that are involved in an arbitration pursuant to a pre-dispute arbitration agreement to submit specified arbitral records to the Bureau and also to submit specified court records. The Bureau is also adopting official interpretations to the regulation.

The Arbitration Rule’s effective date is 60 days following its publication in the Federal Register (which is imminent), and it applies to contracts entered into more than 180 days after that.

Cutting through the hyperbole that the Arbitration Rule protects consumers from “unfairness” that would deny them “their day in court,” this Rule is in fact highly anti-consumer and harmful to innovation.  As Competitive Enterprise Senior Fellow John Berlau put it, in promulgating this Rule, “[t]he CFPB has disregarded vast data showing that arbitration more often compensates consumers for damages faster and grants them larger awards than do class action lawsuits. This regulation could have particularly harmful effects on FinTech innovations, such as peer-to-peer lending.”  Moreover, in a coauthored paper, Professors Jason Johnston of the University of Virginia Law School and Todd Zywicki of the Scalia Law School debunked a CFPB study that sought to justify the agency’s plans to issue the Arbitration Rule.  They concluded:

The CFPB’s [own] findings show that arbitration is relatively fair and successful at resolving a range of disputes between consumers and providers of consumer financial products, and that regulatory efforts to limit the use of arbitration will likely leave consumers worse off . . . .  Moreover, owing to flaws in the report’s design and a lack of information, the report should not be used as the basis for any legislative or regulatory proposal to limit the use of consumer arbitration.    

Unfortunately, the Arbitration Rule is just the latest of many costly regulatory outrages perpetrated by the CFPB, an unaccountable bureaucracy that offends the Constitution’s separation of powers and should be eliminated by Congress, as I explained in a 2016 Heritage Foundation report.

Legislative elimination of an agency, however, takes time.  Fortunately, in the near term, Congress can apply the Congressional Review Act (CRA) to prevent the Arbitration Rule from taking effect, and to block the CFPB from passing rules similar to it in the future.

As Heritage Senior Legal Fellow Paul Larkin has explained:

[The CRA is] Congress’s most recent effort to trim the excesses of the modern administrative state.  The act requires the executive branch to report every “rule” — a term that includes not only the regulations an agency promulgates, but also its interpretations of the agency’s governing laws — to the Senate and House of Representatives so that each chamber can schedule an up-or-down vote on the rule under the statute’s fast-track procedure.  The act was designed to enable Congress expeditiously to overturn agency regulations by avoiding the delays occasioned by the Senate’s filibuster rules and practices while also satisfying the [U.S. Constitution’s] Article I Bicameralism and Presentment requirements, which force the Congress and President to collaborate to enact, revise, or repeal a law.  Under the CRA, a joint resolution of disapproval signed into law by the President invalidates the rule and bars an agency from thereafter adopting any substantially similar rule absent a new act of Congress.

Although the CRA was almost never invoked before 2017, in recent months it has been used extensively as a tool by Congress and the Trump Administration to roll back specific manifestations Obama Administration regulatory overreach (for example, see here and here).

Application of the CRA to expunge the Arbitration Rule (and any future variations on it) would benefit consumers, financial services innovation, and the overall economy.  Senator Tom Cotton has already gotten the ball rolling to repeal that Rule.  Let us hope that Congress follows his lead and acts promptly.

We’re delighted to welcome Eric Fruits as our newest blogger at Truth on the Market.

Eric Fruits, Ph.D. is the Oregon Association of Realtors Faculty Fellow at Portland State University and the recently minted Chief Economist at the International Center for Law & Economics.

Eric Fruits

Among other things, Dr. Fruits is an antitrust expert, with particular expertise in price fixing and cartels (see, e.g., his article, Market Power and Cartel Formation: Theory and an Empirical Test, in the Journal of Law and Economics). He has assisted in the review of several mergers including Sysco-US Foods, Exxon-Mobil, BP-Arco, and Nestle-Ralston. He has worked on numerous antitrust lawsuits, including Weyerhaeuser v. Ross-Simmons, a predatory bidding case that was ultimately decided by the US Supreme Court (and discussed at some length by Thom here on TOTM: See here and here).

As an expert in statistics, he has provided expert opinions and testimony regarding market manipulation, real estate transactions, profit projections, agricultural commodities, and war crimes allegations. His expert testimony has been submitted to state courts, federal courts, and an international court.

Eric has also written peer-reviewed articles on insider trading, initial public offerings (IPOs), and the municipal bond market, among many other topics. His economic analysis has been widely cited and has been published in The Economist and the Wall Street Journal. His testimony regarding the economics of public employee pension reforms was heard by a special session of the Oregon Supreme Court.

You can also find him on Twitter at @ericfruits

Welcome, Eric!

 

 

  1. Background

On June 19, in Matal v. Tam, the U.S. Supreme Court (Justice Gorsuch did not participate in the case) affirmed the Federal Circuit’s ruling that the Lanham Act’s “disparagement clause” is unconstitutional under the First Amendment’s free speech clause.  The Patent and Trademark Office denied the Slants’ (an Asian rock group) federal trademark registration, relying on the Lanham Act’s prohibition on trademarks that “which may disparage . . . persons, living or dead, institutions, beliefs, or national symbols, or bring them into contempt, or disrepute.”  The Court held that trademarks are not government speech, pointing out that the government “does not dream up these marks.”  With the exception of marks scrutinized under the disparagement clause, trademarks are not reviewed for compliance with government policies.  Writing for the Court, Justice Samuel Alito (joined by Chief Justice John Roberts, Justice Clarence Thomas, and Justice Stephen Breyer) found unpersuasive the government’s argument that trademarks are analogous to subsidized speech.  The Alito opinion also determined that it is unnecessary to determine whether trademarks are commercial speech (subject to lesser scrutiny), because the disparagement clause cannot survive the Supreme Court’s test for such speech enunciated in Central Hudson Gas & Electric Company (1980).  Justice Anthony Kennedy, joined by Justices Ruth Bader Ginsburg, Sonia Sotomayor, and Elena Kagan, concurred in the judgment.  The Kennedy opinion agreed that the disparagement clause constitutes viewpoint discrimination because it reflects the government’s disapproval of certain speech, and that heightened scrutiny should apply, whether or not trademarks are commercial speech.

The Tam decision continues the trend of Supreme Court cases extending First Amendment protection for offensive speech.  Perhaps less likely to be noted, however, is that this decision also promotes free market principles by enhancing the effectiveness of legal protection for a key intellectual property right.  To understand this point, a brief primer on the law and economics of federal trademark protection is in order.

  1. The Law and Economics of Federal Trademark Protection in a Nutshell

A trademark (called a service mark in the case of a service) is an intellectual property right that identifies the source of a particular producer’s goods or services.  Trademarks reduce transactions costs by enabling consumers more easily to identify and patronize particular goods and services whose attributes they associate with a trademark.  This enhances market efficiency, by lowering information costs in the market and by encouraging competing firms to develop unique attributes that they can signal to consumers.

By robustly protecting federally-registered trademarks, the federal Lanham Act (see here for Lanham Act trademark infringement remedies) creates strong incentives for each trademark holder to invest in (and promote through advertising and other means) the quality of the trademarked goods or services it produces.  Strong trademark remedies are key because they promote the market-based interest in ensuring trademark holders that their individual property rights will be protected.  As one scholar puts it, “[i]t is generally accepted that [federal trademark] infringement actions protect both the goodwill of mark owners and competition by preventing confusion.”

Shielded by firm legal protection, the trademark holder will tend not to allow the quality of its trademark-protected offerings to slip, knowing that consumers will quickly and easily associate the reduced quality with its mark and stop patronizing the trademarked product or service.  Absent strong trademark protection, however, producers of competing products and services will be tempted to “free ride” by using a competing business’s registered trademark without authorization.  This sharply reduces the original trademark owner’s incentive to invest in and continue to promote quality, because it knows that the free riders will seek to attract customers by using the trademark to sell less costly, lower quality fare.  Quality overall suffers, to the detriment of consumers.  Allowing free riding on distinctive trademarks also (and relatedly) sows confusion as to the identity of sellers and as to the attributes covered by a particular trademark, leading to a weakening of the trademark system’s role as a source identifier and as a spur to attribute-based competition.

In short, federal trademark law protection, embodied in the Lanham Act, enhances free market competitive processes by protecting a trademark’s role in identifying suppliers (reducing transaction costs); incentivizing investment in the enhancement and preservation of product quality; and spurring attribute-based competition.

  1. The Demise of Lanham Act Disparagement Enhances Trademark Rights and Promotes Free Market Principles

The disparagement clause denied federal legal protection to a broad class of trademarks, based merely on the highly subjective determination by federal bureaucrats that the marks in question “disparaged” particular individuals or institutions.  This denial undermined private parties’ incentives to invest in “disparaging” marks, and to compete vigorously by signaling to consumers the existence of novel products and services that they might find appealing.

By “constitutionally expunging” the disparagement clause, the Supreme Court in Tam has opened the gateway to more robust competition by spurring the vigorous investment in and promotion of a larger number of marks.  Consumers in the marketplace, not bureaucrats, will decide whether the products or services identified by particular marks are “problematic” and therefore not worthy of patronage.  In other words, by enhancing legal protection for a wider variety of trademarks, the Tam decision has paved the way for the expansion of mutually-beneficial marketplace transactions, to the benefit of consumers and producers alike.

To conclude, in promoting First Amendment free speech interests, the Tam Court also gave a shot in the arm to welfare-enhancing competition in markets for goods and services.  It turns out that competition in the marketplace of ideas goes hand-in-hand with competition in the commercial marketplace.

Too much ink has been spilled in an attempt to gin up antitrust controversies regarding efforts by holders of “standard essential patents” (SEPs, patents covering technologies that are adopted as part of technical standards relied upon by manufacturers) to obtain reasonable returns to their property. Antitrust theories typically revolve around claims that SEP owners engage in monopolistic “hold-up” when they threaten injunctions or seek “excessive” royalties (or other “improperly onerous” terms) from potential licensees in patent licensing negotiations, in violation of pledges (sometimes imposed by standard-setting organizations) to license on “fair, reasonable, and non-discriminatory” (FRAND) terms. As Professors Joshua Wright and Douglas Ginsburg, among others, have explained, contract law, tort law, and patent law are far better placed to handle “FRAND-related” SEP disputes than antitrust law. Adding antitrust to the litigation mix generates unnecessary costs and inefficiently devalues legitimate private property rights.

Concerns by antitrust mavens that other areas of law are insufficient to cope adequately with SEP-FRAND disputes are misplaced. A fascinating draft law review article by Koren Wrong-Ervin, Director of the Scalia Law School’s Global Antitrust Institute, and Anne Layne-Farrar, Vice President of Charles River Associates, does an admirable job of summarizing key decisions by U.S. and foreign courts involved in determining FRAND rates in SEP litigation, and in highlighting key economic concepts underlying these holdings. As explained in the article’s abstract:

In the last several years, courts around the world, including in China, the European Union, India, and the United States, have ruled on appropriate methodologies for calculating either a reasonable royalty rate or reasonable royalty damages on standard-essential patents (SEPs) upon which a patent holder has made an assurance to license on fair, reasonable and nondiscriminatory (FRAND) terms. Included in these decisions are determinations about patent holdup, licensee holdout, the seeking of injunctive relief, royalty stacking, the incremental value rule, reliance on comparable licenses, the appropriate revenue base for royalty calculations, and the use of worldwide portfolio licensing. This article provides an economic and comparative analysis of the case law to date, including the landmark 2013 FRAND-royalty determination issued by the Shenzhen Intermediate People’s Court (and affirmed by the Guangdong Province High People’s Court) in Huawei v. InterDigital; numerous U.S. district court decisions; recent seminal decisions from the United States Court of Appeals for the Federal Circuit in Ericsson v. D-Link and CISCO v. CSIRO; the six recent decisions involving Ericsson issued by the Delhi High Court; the European Court of Justice decision in Huawei v. ZTE; and numerous post- Huawei v. ZTE decisions by European Union member states. While this article focuses on court decisions, discussions of the various agency decisions from around the world are also included throughout.   

To whet the reader’s appetite, key economic policy and factual “takeaways” from the article, which are reflected implicitly in a variety of U.S. and foreign judicial holdings, are as follows:

  • Holdup of any form requires lock-in, i.e., standard-implementing companies with asset-specific investments locked in to the technologies defining the standard or SEP holders locked in to licensing in the context of a standard because of standard-specific research and development (R&D) leading to standard-specific patented technologies.
  • Lock-in is a necessary condition for holdup, but it is not sufficient. For holdup in any guise to actually occur, there also must be an exploitative action taken by the relevant party once lock-in has happened. As a result, the mere fact that a license agreement was signed after a patent was included in a standard is not enough to establish that the patent holder is practicing holdup—there must also be evidence that the SEP holder took advantage of the licensee’s lock-in, for example by charging supra-FRAND royalties that it could not otherwise have charged but for the lock-in.
  • Despite coming after a particular standard is published, the vast majority of SEP licenses are concluded in arm’s length, bilateral negotiations with no allegations of holdup or opportunistic behavior. This follows because market mechanisms impose a number of constraints that militate against acting on the opportunity for holdup.
  • In order to support holdup claims, an expert must establish that the terms and conditions in an SEP licensing agreement generate payments that exceed the value conveyed by the patented technology to the licensor that signed the agreement.
  • The threat of seeking injunctive relief, on its own, cannot lead to holdup unless that threat is both credible and actionable. Indeed, the in terrorem effect of filing for an injunction depends on the likelihood of its being granted. Empirical evidence shows a significant decline in the number of injunctions sought as well as in the actual rate of injunctions granted in the United States following the Supreme Court’s 2006 decision in eBay v. MercExchange LLC, which ended the prior nearly automatic granting of injunctions to patentees and instead required courts to apply a traditional four-part equitable test for granting injunctive relief.
  • The Federal Circuit has recognized that an SEP holder’s ability to seek injunctive relief is an important safeguard to help prevent potential licensee holdout, whereby an SEP infringer unilaterally refuses a FRAND royalty or unreasonably delays negotiations to the same effect.
  • Related to the previous point, seeking an injunction against a licensee who is delaying or not negotiating in good faith need not actually result in an injunction. The fact that a court finds a licensee is holding out and/or not engaging in good faith licensing discussions can be enough to spur a license agreement as opposed to a permanent injunction.
  • FRAND rates should reflect the value of the SEPs at issue, so it makes no economic sense to estimate an aggregate rate for a standard by assuming that all SEP holders would charge the same rate as the one being challenged in the current lawsuit.
  • Moreover, as the U.S. Court of Appeals for the Federal Circuit has held, allegations of “royalty stacking” – the allegedly “excessive” aggregate burden of high licensing fees stemming from multiple patents that cover a single product – should be backed by case-specific evidence.
  • Most importantly, when a judicial FRAND assessment is focused on the value that the SEP portfolio at issue has contributed to the standard and products embodying the standard, the resulting rates and terms will necessarily avoid both patent holdup and royalty stacking.

In sum, the Wong-Ervin and Layne-Farrar article highlights economic insights that are reflected in the sounder judicial opinions dealing with the determination of FRAND royalties.  The article points the way toward methodologies that provide SEP holders sufficient returns on their intellectual property to reward innovation and maintain incentives to invest in technologies that enhance the value of standards.  Read it and learn.

Today, the Senate Committee on Health, Education, Labor, and Pensions (HELP) enters the drug pricing debate with a hearing on “The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay.”  By questioning the role of the drug delivery system in pricing, the hearing goes beyond the more narrow focus of recent hearings that have explored how drug companies set prices.  Instead, today’s hearing will explore how pharmacy benefit managers, insurers, providers, and others influence the amounts that patients pay.

In 2016, net U.S. drug spending increased by 4.8% to $323 billion (after adjusting for rebates and off-invoice discounts).  This rate of growth slowed to less than half the rates of 2014 and 2015, when net drug spending grew at rates of 10% and 8.9% respectively.  Yet despite the slowing in drug spending, the public outcry over the cost of prescription drugs continues.

In today’s hearing, there will be testimony both on the various causes of drug spending increases and on various proposals that could reduce the cost of drugs.  Several of the proposals will focus on ways to increase competition in the pharmaceutical industry, and in turn, reduce drug prices.  I have previously explained several ways that the government could reduce prices through enhanced competition, including reducing the backlog of generic drugs awaiting FDA approval and expediting the approval and acceptance of biosimilars.  Other proposals today will likely call for regulatory reforms to enable innovative contractual arrangements that allow for outcome- or indication-based pricing and other novel reimbursement designs.

However, some proposals will undoubtedly return to the familiar call for more government negotiation of drug prices, especially drugs covered under Medicare Part D.  As I’ve discussed in a previous post, in order for government negotiation to significantly lower drug prices, the government must be able to put pressure on drug makers to secure price concessions. This could be achieved if the government could set prices administratively, penalize manufacturers that don’t offer price reductions, or establish a formulary.  Setting prices or penalizing drug makers that don’t reduce prices would produce the same disastrous effects as price controls: drug shortages in certain markets, increased prices for non-Medicare patients, and reduced incentives for innovation. A government formulary for Medicare Part D coverage would provide leverage to obtain discounts from manufacturers, but it would mean that many patients could no longer access some of their optimal drugs.

As lawmakers seriously consider changes that would produce these negative consequences, industry would do well to voluntarily constrain prices.  Indeed, in the last year, many drug makers have pledged to limit price increases to keep drug spending under control.  Allergan was first, with its “social contract” introduced last September that promised to keep price increases below 10 percent. Since then, Novo Nordisk, AbbVie, and Takeda, have also voluntarily committed to single-digit price increases.

So far, the evidence shows the drug makers are sticking to their promises. Allergan has raised the price of U.S. branded products by an average of 6.7% in 2017, and no drug’s list price has increased by more than single digits.  In contrast, Pfizer, who has made no pricing commitment, has raised the price of many of its drugs by 20%.

If more drug makers brought about meaningful change by committing to voluntary pricing restraints, the industry could prevent the market-distorting consequences of government intervention while helping patients afford the drugs they need.   Moreover, avoiding intrusive government mandates and price controls would preserve drug innovation that has brought life-saving and life-enhancing drugs to millions of Americans.